Jefferies, BMO Capital Markets and Wells Fargo will be the bookrunners
By Devika Patel
Knoxville, Tenn., Feb. 7 - Five Prime Therapeutics, Inc. said it priced a $37.5 million public sale of stock with a $5.63 million greenshoe on Thursday. The deal was announced Jan. 22.
The company will sell 3 million common shares at $12.50 per share. The price per share is an 0.87% discount to the Feb. 5 closing share price of $12.61.
Jefferies, BMO Capital Markets and Wells Fargo Securities are the joint bookrunning managers.
Settlement is expected Feb. 12.
The clinical-stage biotechnology company is based in South San Francisco, Calif.
Issuer: | Five Prime Therapeutics, Inc.
|
Issue: | Common stock
|
Amount: | $37.5 million
|
Greenshoe: | $5,625,000
|
Shares: | 3 million
|
Price: | $12.50
|
Warrants: | No
|
Bookrunners: | Jefferies LLC, BMO Capital Markets and Wells Fargo Securities, LLC
|
Co-manager: | Guggenheim Securities, LLC
|
Announcement date: | Jan. 22
|
Pricing date: | Feb. 6
|
Settlement date: | Feb. 12
|
Stock symbol: | Nasdaq: FPRX
|
Stock price: | $12.61 at close Feb. 5
|
Market capitalization: | $232.98 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.